title: Utilizing the protein corona around silica nanoparticles for dual drug loading and release.
abstract: A protein corona forms spontaneously around silica nanoparticles (SNPs) in serum-containing media. To test whether this protein corona can be utilized for the loading and release of anticancer drugs we incorporated the hydrophilic doxorubicin, the hydrophobic meloxicam as well as their combination in the corona around SNPs. The application of corona-covered SNPs to osteosarcoma cells revealed that drug-free particles did not affect the cell viability. In contrast, SNPs carrying a protein corona with doxorubicin or meloxicam lowered the cell proliferation in a concentration-dependent manner. In addition, these particles had an even greater antiproliferative potential than the respective concentrations of free drugs. The best antiproliferative effects were observed for SNPs containing both doxorubicin and meloxicam in their corona. Co-localization studies revealed the presence of doxorubicin fluorescence in the nucleus and lysosomes of cells exposed to doxorubicin-containing coated SNPs, suggesting that endocytotic uptake of the SNPs facilitates the cellular accumulation of the drug. Our data demonstrate that the protein corona, which spontaneously forms around nanoparticles, can be efficiently exploited for loading the particles with multiple drugs for therapeutic purposes. As drugs are efficiently released from such particles they may have a great potential for nanomedical applications.
authors.affiliation: Advanced Ceramics, University of Bremen, Am Biologischen Garten 2, 28359 Bremen, Germany. treccani@uni-bremen.de.
authors.forename: Shakiba
authors.initials: S
authors.lastname: Shahabi
authors.forename: Laura
authors.initials: L
authors.lastname: Treccani
authors.forename: Ralf
authors.initials: R
authors.lastname: Dringen
authors.forename: Kurosch
authors.initials: K
authors.lastname: Rezwan
mesh_terms: D001798:Blood Proteins / Q000737:chemistry*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004317:Doxorubicin / Q000737:chemistry / Q000494:pharmacology; D004337:Drug Carriers / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D000077239:Meloxicam; D053758:Nanoparticles / Q000737:chemistry*; D012516:Osteosarcoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D012822:Silicon Dioxide / Q000737:chemistry*; D013843:Thiazines / Q000737:chemistry / Q000494:pharmacology; D013844:Thiazoles / Q000737:chemistry / Q000494:pharmacology
chemical_list: D001798:Blood Proteins; D004337:Drug Carriers; D013843:Thiazines; D013844:Thiazoles; D012822:Silicon Dioxide; D004317:Doxorubicin; D000077239:Meloxicam